CROI 2014: Viral hepatitis and complications of HIV disease and antiretroviral therapy

Topics in Antiviral Medicine

Volumn 22, Issue 2, 2014, Pages 602-615

  Luetkemeyer, Anne F ^a   Havlir, Diane V ^b   Currier, Judith S ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aging; Antiretroviral therapy; Bone; Cardiovascular disease; Coinfection; Comorbidities; CROI 2014; Direct acting antivirals; HCV; Hepatitis C virus; HIV; Kaposi sarcoma; Tuberculosis

Indexed keywords

ANTIVIRUS AGENT; TUBERCULOSTATIC AGENT;

COMPLICATION; DRUG INTERACTION; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMAN; TREATMENT OUTCOME; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; ANTIVIRAL AGENTS; DRUG INTERACTIONS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84906851923     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Zeuzem S, Dusheiko GM, Salupere R. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. Hepatology. 2013;58(S1):733A-734A.
2. AbbVie. AbbVie completes largest phase III program of an all-oral, interferon-free therapy for the treatment of hepatitis C genotype 1 [press release]. http://abbvie.mediaroom.com/2014-01-31-AbbVie- Completes-Largest-Phase-III-Programof-an-All-Oral-Interferon-Free-Therapy-forthe-Treatment-of-Hepatitis-C-Genotype-1. Accessed on March 31, 2014.
3. Lawitz E, Vierling J, Murillo A, et al. High efficacy and safety of the all-oral combination regimen, MK-5172/MK-8742 +/- RBV for 12 weeks in HCV genotype 1 infected patients: the C-WORTHY study. 24th Conference of the Asian Pacific Association for the Study of the Liver. March 12- 15, 2014; Brisbane, Australia.
4. Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013;310(8):804-811.
5. Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with Peginterferon and Ribavirin Leads to High Rates of SVR in Patients with HCV Genotype 1 Who Relapsed After Previous Therapy: a Phase 3 Trial. Gastroenterology. 2014;[Epub ahead of print].
6. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology. 2014; 146(2):430-441.
7. Fried MW, Buti M, Dore GJ, et al. Oncedaily simeprevir (TMC435) with pegylated interferon and ribavirin in treatmentnaive genotype 1 hepatitis C: The randomized PILLAR study. Hepatology. 2013; 58(6):1918-1929.
8. Janssen Therapeutics. Simeprevir [package insert]. 2013.Titusville, NJ, Janssen Therapeutics.
9. Jacobson IM, Ghalib RH, Rodriguez-Torres M, et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: The COSMOS study. Hepatology. 2013;58(6):1379A- 1380A.
10. Ferenci P, Asselah T, Foster GR, et al. 1416 Faldaprevir plus pegylated interferon alfa-2a and ribavirin in chronic HCV genotype-1 treatment-naïve patients: Final results from STARTVerso1, a randomised, double-blind, placebo-controlled phase III trial. J Hepatol. 2013;58(Supp 1): S569-S570.
11. Jensen DM, Asselah T, Dieterich DT, et al. A pooled analysis of two randomized, double-blind placebo-controlled phase III trials (STARTVerso1&2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment naive patients with chronic hepatitis C genotype-1 infection. Hepatology. 2013;58(S1):734A-735A.
12. Heidrich B, Yurdaydin C, Kabacam G, et al. Late HDV RNA relapse after peginterferon alfa-based therapy of chronic hepatitis delta. Hepatology. 2014;[Epub ahead of print].
13. Abbas Z, Memon MS, Mithani H, Jafri W, Hamid S. Treatment of chronic hepatitis D patients with pegylated interferon: a real world experience. Antivir Ther. 2014;[Epub ahead of print].
14. Crum-Cianflone NF, Curry J, Drobeniuc J, et al. Hepatitis E virus infection in HIVinfected persons. Emerg Infect Dis. 2012; 18(3):502-506.
15. Renou C, Lafeuillade A, Cadranel JF, et al. Hepatitis E virus in HIV-infected patients. AIDS. 2010;24(10):1493-1499.
16. Kaba M, Richet H, Ravaux I, et al. Hepatitis E virus infection in patients infected with the human immunodeficiency virus. J Med Virol. 2011;83(10):1704-1716.
17. Keane F, Gompels M, Bendall R, et al. Hepatitis E virus coinfection in patients with HIV infection. HIV Med. 2012;13(1):83-88.
18. Maylin S, Stephan R, Molina JM, et al. Prevalence of antibodies and RNA genome of hepatitis E virus in a cohort of French immunocompromised. J Clin Virol. 2012;53(4):346-349.
19. Crowe SM, Hoy JF. Are monocytes the canary in the coal mine for HIVrelated atherosclerosis? J Infect Dis. 2012;206(10):1491-1493.
20. Funderburg NT, Zidar DA, Shive C, et al. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood. 2012;120(23):4599-4608.
21. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203(6):780-790.
22. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506-2512.
23. Subramanian S, Tawakol A, Burdo TH, et al. Arterial inflammation in patients with HIV. JAMA. 2012;308(4):379-386.
24. Secemsky E, Scherzer R, Nitta E et al. ST2 and NT-proBNP are associated with cardiac dysfunction and mortality in HIV+ individuals [Abstract 749]. 20th Conference on Retroviruses and Opportunistic Infections (CROI). March 3-6, 2013; Atlanta, Georgia.
25. Strategies for Management of Antiretroviral Therapy/INSIGHT, D:A:D Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22:F17-F24.
26. McComsey G, Jiang Y, Debanne S et al. Effect of statins on immune activation and inflammation in HIV+ subjects on ART: a randomized placebo controlled trial [Abstract 186LB]. 20th Conference on Retroviruses and Opportunistic Infections (CROI). March 3-6, 2013; Atlanta, Georgia.
27. Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis. 2014;58(4):588-595.
28. World Health Organization (WHO). WHO endorses new rapid tuberculosis test: a major milestone for global TB diagnosis and care. http://www.who.int/mediacentre/news/releases/2010/tb_test_20101208/en/. Accessed on April 11, 2014.
29. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155-2166.
30. Asselah T, Marcellin P. Interferon free therapy with direct acting antivirals for HCV. Liver Int. 2013;33 (Suppl 1):93-104.